Skip to main content
. 2023 Nov 16;7:e2300197. doi: 10.1200/PO.23.00197

FIG 3.

FIG 3.

(A and B) TNBC molecular subtype and immunomodulatory status in the (A) S9313 and (B) TCGA TNBC cohorts. (C) Distribution of sTIL frequency and fraction of tumors with ≥30 sTILs within the S9313 TNBC cohort. For continuous comparison, P is Kruskal-Wallis test with Dunn's multiple comparison correction. For comparison by ≥30% threshold, P is Fisher-Freeman-Halton test. (D) sTIL frequency in the TCGA TNBC cohort. P is Kruskal-Wallis test with Dunn's multiple comparison correction. *<0.05, **<0.01, ***<0.001, ****<0.0001. (E and F) Relative CIBERSORTx leukocyte fractions within the (E) S9313 and (F) TCGA TNBC cohorts. Heatmap reflects mean leukocyte fraction within DDIR/HRD class with upper and lower inset boxes reflecting mean + SE and mean - SE, respectively. Red boxes in grids denote significant differences for each comparison (FDR <0.05). (G and H) Expression of PD-1, PD-L1, and CTLA4 by DDIR/HRD class in the (G) S9313 and (H) TCGA TNBC cohorts. P is Kruskal-Wallis test with Dunn's multiple comparison correction. Binary comparisons by DDIR or HRD status alone are Mann-Whitney, with *<0.05, **<0.01, ***<0.001, ****<0.0001. DDIR, DNA damage immune response; FDR, false discovery rate; HRD, homologous recombination deficiency; sTIL, stromal tumor infiltrating lymphocyte; TCGA, The Cancer Genome Atlas; TNBC, triple-negative breast cancer.